Treatment-driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B-cell therapy in Sjögren's disease. (PubMed, Arthritis Rheumatol) - Sep 25, 2026 - P2 | "The distinct ESSDAI and STAR ligand-receptor signatures indicate different systemic biological drivers of non-response to B-cell therapies in SjD. Their complete non-overlap suggests entrenched B-cell-independent inflammatory circuits, highlighting complement regulation, TGFB2-mediated remodelling, IL-1/IL-18 signalling and FcγR activation as rational treatment pathways beyond B-cell-targeted therapies."
Journal • Sjogren's Syndrome • CD8 • FCGR2A • IL18 • IL1R1 • IL1RAP • SPP1 • STAR • TGFB2 • TLR4
|
|
Aimen Ibrahim; Andre van Maurik; Coziana Ciurtin; Eileen Tian; Elizabeth C Jury; John Casement; Junjie Peng; Kyle Thompson; Lucia Martin-Gutierrez; Wan-Fai Ng
|